Search results
Showing 346 to 360 of 501 results for cost benefit of cancer drugs
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer (TA1177)
Evidence-based recommendation on pembrolizumab (Keytruda) with chemoradiotherapy for untreated locally advanced cervical cancer in adults.
Show all sections
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.
Evidence-based recommendations on zanidatamab (Ziihera) for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment in adults.
Show all sections
Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)
Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.